23.35
+0.59(+2.59%)
Currency In USD
| Previous Close | 22.76 |
| Open | 23.1 |
| Day High | 23.55 |
| Day Low | 22.9 |
| 52-Week High | 26.16 |
| 52-Week Low | 14.47 |
| Volume | 419,896 |
| Average Volume | 1.26M |
| Market Cap | 2.85B |
| PE | 17.82 |
| EPS | 1.31 |
| Moving Average 50 Days | 22.93 |
| Moving Average 200 Days | 21.44 |
| Change | 0.59 |
If you invested $1000 in Catalyst Pharmaceuticals, Inc. (CPRX) 10 years ago, it would be worth $6,847.51 as of May 09, 2025 at a share price of $23.35. Whereas If you bought $1000 worth of Catalyst Pharmaceuticals, Inc. (CPRX) shares 5 years ago, it would be worth $4,623.76 as of May 09, 2025 at a share price of $23.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025
GlobeNewswire Inc.
Apr 30, 2025 12:03 PM GMT
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines fo
Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025
GlobeNewswire Inc.
Apr 22, 2025 12:03 PM GMT
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ETCORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical c
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
GlobeNewswire Inc.
Apr 08, 2025 12:06 PM GMT
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines fo